Illumina, Inc. (ILMN) fundamentals: P/E, valuation, undervalued?
Illumina, Inc. · Health Care · ref. ETF XLV · price $271.18
In short — Illumina, Inc. trades at 50.3× earnings (P/E), 44.3× forward, with a net margin of 18.3 % and revenue growth of +9 %. Read: High P/E (P/E 50 (above average)).
Is Illumina, Inc. stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$271.18+198.0% over range
Oct 14, 25low $91 · high $293.69Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
69% recommend buying · 13 analysts
Valuation : High P/E — P/E 50 (above average)
Valuation
50.3
P/E (price/earnings)
44.3
Forward P/E
—
PEG
14.4
Price/book (P/B)
$40.9B
Market cap
5.39
EPS
Profitability & growth
18.3 %
Net margin
+9 %
Revenue growth
-9 %
Earnings growth
$2.5B
Total debt
Illumina, Inc. income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $4.6B | $-4.4B | -96.1 % |
| 2023 | $4.5B | $-1.2B | -25.8 % |
| 2024 | $4.4B | $-1.2B | -28.0 % |
| 2025 | $4.3B | $850M | 19.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Illumina, Inc.'s P/E and is the stock undervalued? What's a good P/E?
Illumina, Inc.'s P/E is 50.3 (forward 44.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "High P/E".
Is Illumina, Inc. profitable?
Illumina, Inc. has a net margin of 18.3 % (EPS 5.39). The company is profitable.
Is ILMN stock expensive?
Our read: "High P/E" — P/E 50 (above average). Cross-check with growth and sector.
💬 A question about Illumina, Inc.? The JPI assistant answers using our backtest data.